Therapeutic agent for fibrosis and inhibitor of nuclear translocation of phosphorylated smad
AssigneeNational University Corporation Chiba University
InventorsHiroyuki NAKAMURA, Toshihiko MURAYAMA
Life of this patent
Estimating the term…
Abstract
A therapeutic agent for fibrosis, whose active ingredient is constituted by a glucosylceramide synthase inhibitor or lactosylceramide synthase inhibitor, or both, inhibits the nuclear translocation of phosphorylated Smad, thereby treating and preventing fibrosis.
Claims10
A therapeutic agent for fibrosis characterized in that its active ingredient is a glucosylceramide synthase inhibitor or a lactosylceramide synthase inhibitor, or both.
An inhibitor of nuclear translocation of phosphorylated Smad, whose active ingredient is a glucosylceramide synthase inhibitor or a lactosylceramide synthase inhibitor, or both.
A method for treating fibrosis, a disorder characterized by fibrosis, or a disease characterized by fibrosis, comprising administrating an therapeutic agent for fibrosis whose active ingredient is constituted by a glucosylceramide synthase inhibitor or lactosylceramide synthase inhibitor, or both, which inhibitor has the activity of inhibiting nuclear translocation of phosphorylated Smad and is contained in a therapeutically effective amount.
Dependencies are inferred from the claim text.